Omeprazole (A2845): Technical Guide for Gastric Acid Secretion and Antiulcer Studies

What This Product Solves

Omeprazole, chemically known as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a potent H+,K+-ATPase inhibitor with an IC50 of 5.8 μM. It is designed to enable controlled inhibition of gastric acid secretion in experimental models, making it integral to gastric acid secretion research, antiulcer activity studies, and investigations into peptic ulcer disease models. The compound's efficacy in reducing acid formation (IC50 = 0.16 μM for histamine-induced acid production) offers a robust tool for interrogating gastric acid-related disorders and refining antiulcer agent workflows (product_spec).

For advanced mechanistic studies and benchmarking of proton pump inhibitors, Omeprazole’s solubility and purity characteristics are critical for reproducibility and troubleshooting. The product is not intended for diagnostic or medical use but is validated for research applications requiring precise acid suppression.

For broader context on workflow strategies and advanced applications (e.g., gut–brain axis), see the in-depth dossier on Expanding Horizons and a technical review on Applied Research with 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide.

Protocol Parameters

• assay: H+,K+-ATPase inhibition
  value_with_unit: IC50 = 5.8 μM
  applicability: Quantitative assessment of proton pump inhibition in in vitro or ex vivo models.
  rationale: Establishes baseline efficacy and supports dose selection for gastric acid suppression.
  source_type: product_spec
• assay: Histamine-induced gastric acid formation inhibition
  value_with_unit: IC50 = 0.16 μM
  applicability: For studies modeling acid secretion in response to histamine stimulation.
  rationale: Demonstrates potent suppression in relevant physiological triggers of acid secretion.
  source_type: product_spec
• assay: Solubility in DMSO
  value_with_unit: ≥17.27 mg/mL
  applicability: Required for preparing concentrated stock solutions for cell-based and tissue assays.
  rationale: Ensures sufficient compound delivery and minimizes precipitation during dosing.
  source_type: product_spec
• assay: Long-term solution stability
  value_with_unit: Not recommended
  applicability: Impacts experimental design where pre-prepared solutions may be stored.
  rationale: Omeprazole solutions are prone to degradation; prepare fresh aliquots for each use.
  source_type: product_spec

Workflow Setup and QC Checklist

• Compound Handling: Store Omeprazole as a dry solid at -20°C. Avoid repeated freeze-thaw cycles to maintain the stated 98% purity.
• Stock Preparation: Dissolve in DMSO to prepare concentrated stocks. The compound is insoluble in water and ethanol; attempts to dissolve in these solvents may result in precipitation and reduced bioavailability.
• Aliquoting: Prepare single-use aliquots to avoid repeated freeze-thaw, which accelerates degradation.
• Shipping Verification: For small molecule orders, confirm blue ice inclusion upon delivery to maintain stability.
• Pre-use QC: Visually inspect the solid for discoloration or clumping. If observed, discard and reconstitute from a new vial.
• Experimental Controls: Always include vehicle-only controls (DMSO) to exclude solvent effects in cell-based or tissue experiments.
• Documentation: Record batch number, solubility, and storage history for reproducibility and troubleshooting.

Common Failure Modes and Fixes

• Precipitation in Aqueous Solution: If Omeprazole precipitates upon dilution, confirm use of DMSO stock and gradual mixing into buffer. Do not exceed recommended DMSO concentrations compatible with your assay system.
• Loss of Activity in Stored Solutions: Omeprazole is unstable in solution over time—prepare fresh working solutions for each experiment and avoid long-term storage in solvent (product_spec).
• Batch-to-Batch Variability: Purity is ~98%, but always confirm lot number and request updated COA from supplier if discrepancies are suspected.
• False Negative Results: Ensure correct stock concentration and complete dissolution. Suboptimal solubilization or incorrect dosing may yield misleading results in gastric acid secretion or antiulcer activity assays.

Scope and Limitations

• Intended Use: Omeprazole (A2845) is for scientific research only. It is not suitable for diagnostic, therapeutic, or clinical applications.
• Solubility Constraints: Due to insolubility in water and ethanol, this product is limited to DMSO-based workflows. Incompatibility with aqueous-based or in vivo delivery without specialized formulation must be considered.
• Stability: Only the solid form is suitable for long-term storage. Solution form must be freshly prepared and used immediately to prevent degradation.
• Evidence Boundaries: Numeric efficacy data are derived from the product dossier and not from peer-reviewed publications. Mechanistic or translational claims are outside the validated scope unless supported by additional workflow recommendations.

Conclusion

Omeprazole (A2845) from APExBIO is a benchmark H+,K+-ATPase inhibitor for research workflows investigating gastric acid secretion and antiulcer mechanisms. Its potency, defined solubility in DMSO, and high purity streamline experimental setup and reproducibility. Researchers must adhere to specific handling, solubilization, and storage protocols to avoid common failure modes and ensure reliable results. For detailed mechanistic strategies and advanced applications, consult in-depth resources such as Expanding Horizons. For full product specifications and ordering, refer to the Omeprazole product page.